MedPath

Calcitriol

Generic Name
Calcitriol
Brand Names
Rocaltrol, Vectical
Drug Type
Small Molecule
Chemical Formula
C27H44O3
CAS Number
32222-06-3
Unique Ingredient Identifier
FXC9231JVH
Background

Calcitriol is an active metabolite of vitamin D with 3 hydroxyl (OH) groups and is commonly referred to as 1,25-dihydroxycholecalciferol, or 1alpha,25-dihydroxyvitamin D, 1,25-dihydroxyvitamin D. It is produced in the body after series of conversion steps of 7-dehydrocholesterol from exposure to UV light. 7-dehydrocholesterol is converted to Vitamin D3 (vitamin D3) in the skin, which is then converted to Calcifediol in the liver and kidneys. Calcifediol undergoes hydroxylation to form calcitriol via 1α-hydroxylase (CYP27B1) activity . Calcitriol is considered to be the most potent metabolite of vitamin D in humans . Renal production of calcitriol is stimulated in response to PTH, low calcium and low phosphate . Calcitriol plays a role in plasma calcium regulation in concert with parathyroid hormone (PTH) by enhancing absorption of dietary calcium and phosphate from the gastrointestinal tract, promoting renal tubular reabsorption of calcium in the kidneys, and stimulating the release of calcium stores from the skeletal system. In addition to promoting fatty acid synthesis and inhibiting lipolysis, calcitriol has been demonstrated to increase energy efficiency by suppressing UCP2 expression, which is modulated by signaling pathways of classical nuclear receptors (nVDR), where calcitriol acts as a natural ligand . There is also evidence that calcitriol modulates the action of cytokines and may regulate immune and inflammatory response, cell turnover, cell differentiation .

Administered orally and intravenously, calcitriol is commonly used as a medication in the treatment of secondary hyperparathyroidism and resultant metabolic bone disease, hypocalcemia in patients undergoing chronic renal dialysis, and osteoporosis. It is also available in topical form for the treatment of mild to moderate plaque psoriasis in adults. Calcitriol is marketed under various trade names including Rocaltrol (Roche), Calcijex (Abbott) and Decostriol (Mibe, Jesalis).

Indication

Used to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.

Associated Conditions
Hypocalcemia, Mild to Moderate Plaque Psoriasis, Osteodystrophy, Secondary Hyperparathyroidism (SHPT), Vitamin D Resistant Rickets

Effect of 1,25-dihydroxyvitamin D3, Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons

Phase 1
Terminated
Conditions
Pre-Diabetic
Interventions
Drug: Oral Placebo
First Posted Date
2020-02-27
Last Posted Date
2022-04-18
Lead Sponsor
Mayo Clinic
Target Recruit Count
17
Registration Number
NCT04286529
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

A Multicenter Randomized Study of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP

Phase 4
Conditions
Immune Thrombocytopenia
Interventions
First Posted Date
2019-09-19
Last Posted Date
2020-09-09
Lead Sponsor
Shandong University
Target Recruit Count
60
Registration Number
NCT04094805
Locations
🇨🇳

Qilu hospital, Shandong University, Jinan, Shandong, China

Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia

Phase 4
Conditions
X-linked Hypophosphatemia
Interventions
First Posted Date
2019-01-29
Last Posted Date
2019-01-30
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
100
Registration Number
NCT03820518
Locations
🇨🇳

Department of Endocrinology, Peking Union Medical College Hospital, Beijing, Beijing, China

Calcitriol Monotherapy for X-Linked Hypophosphatemia

Early Phase 1
Recruiting
Conditions
X-linked Hypophosphatemia
Hypophosphatemic Rickets, X-Linked Dominant
Hypophosphatemic Rickets
Interventions
First Posted Date
2018-11-21
Last Posted Date
2024-03-12
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
20
Registration Number
NCT03748966
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Clinical Study on Treatment of Postmenopausal Osteoporosis (Kidney Deficiency and Blood Stasis Syndrome) With Xulin Jiangu Granules

Early Phase 1
Conditions
Postmenopausal Osteoporoses
Interventions
First Posted Date
2018-06-20
Last Posted Date
2019-02-26
Lead Sponsor
Fujian Academy of Traditional Chinese Medicine
Target Recruit Count
60
Registration Number
NCT03563235
Locations
🇨🇳

Fujian Academy of Trational Chiness Medicine, Fuzhou, Fujian, China

An Intervention to Examine the Effect of Vitamin D on Urine Protein Levels in Type 2 Diabetes

Phase 3
Conditions
Diabetic Nephropathies
Interventions
First Posted Date
2017-07-13
Last Posted Date
2018-09-06
Lead Sponsor
Hamad Medical Corporation
Target Recruit Count
320
Registration Number
NCT03216564
Locations
🇶🇦

Hamad Medical Corporation, Doha, Qatar

Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis

Phase 3
Completed
Conditions
Facial Angiofibroma
Interventions
Drug: Rapamycin-calcitriol combination
First Posted Date
2017-05-04
Last Posted Date
2017-05-04
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
52
Registration Number
NCT03140449

Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury

Phase 2
Completed
Conditions
Acute Kidney Injury
Critically Ill
Interventions
First Posted Date
2016-11-11
Last Posted Date
2022-02-03
Lead Sponsor
David Leaf
Target Recruit Count
150
Registration Number
NCT02962102
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis

Phase 3
Active, not recruiting
Conditions
Secondary Hyperparathyroidism-Chronic Kidney Disease
Interventions
First Posted Date
2016-08-09
Last Posted Date
2023-04-27
Lead Sponsor
Sanofi
Target Recruit Count
84
Registration Number
NCT02859896
Locations
🇺🇸

Investigational Site Number :8400025, Greenville, North Carolina, United States

🇺🇸

Investigational Site Number :8400015, Jackson, Mississippi, United States

🇺🇸

Investigational Site Number :8400021, Syracuse, New York, United States

and more 27 locations

Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002

Phase 3
Completed
Conditions
Chronic Kidney Disease
Hyperparathyroidism, Secondary
Vitamin D Deficiency
Interventions
First Posted Date
2014-11-04
Last Posted Date
2016-09-29
Lead Sponsor
OPKO Health, Inc.
Target Recruit Count
298
Registration Number
NCT02282813
© Copyright 2025. All Rights Reserved by MedPath